OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Update

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) saw a significant drop in short interest in the month of December. As of December 31st, there was short interest totaling 50,958 shares, a drop of 26.4% from the December 15th total of 69,191 shares. Currently, 0.2% of the shares of the stock are short sold. Based on an average daily volume of 51,695 shares, the short-interest ratio is currently 1.0 days. Based on an average daily volume of 51,695 shares, the short-interest ratio is currently 1.0 days. Currently, 0.2% of the shares of the stock are short sold.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in OKYO Pharma stock. Citadel Advisors LLC acquired a new position in shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 15,355 shares of the company’s stock, valued at approximately $31,000. 2.97% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on OKYO shares. HC Wainwright reiterated a “buy” rating and set a $7.00 price objective on shares of OKYO Pharma in a research note on Tuesday, September 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OKYO Pharma in a report on Wednesday, October 8th. Finally, B. Riley assumed coverage on shares of OKYO Pharma in a research report on Monday, December 8th. They set a “buy” rating and a $5.00 price target on the stock. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $6.00.

OKYO Pharma Price Performance

OKYO stock traded down $0.18 during trading on Friday, reaching $2.21. 183,107 shares of the company were exchanged, compared to its average volume of 166,753. The company has a 50-day moving average of $2.16 and a two-hundred day moving average of $2.37. OKYO Pharma has a twelve month low of $0.90 and a twelve month high of $3.35.

OKYO Pharma Company Profile

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.